What is Claimed is:

5

10

15

- A method of treating a patient for a substance P-related disease, disorder or condition, 1. comprising administering to said patient a therapeutically effective amount of a peptidase that cleaves selectively at Xaa-Pro sequences, wherein said substance Prelated disease, disorder or condition is selected from the group consisting of: a CNS postherpetic pain; neuropathic withdrawal; addiction disorder: neurodegenerative disorder; an autoimmune disease; a disorder of the gastrointestinal tract; a vasospastic disease; a skin disorder or condition; a collagen-related disorder; a cardiovascular disease or condition; an urinary tract disorder; an arthritic disease; an ophthalmic disease or condition; cancer; oedema; emesis; a dysthymic disorder; and reflex sympathetic dystrophy.
 - 2. The method of claim 1, wherein said disease, disorder or condition is a CNS disorder selected from the group consisting of: psychosis; anxiety; and depression.
 - 3. The method of claim 1, wherein said disease, disorder or condition is addiction withdrawal from alcohol or a narcotic.
- 4. The method of claim 1, wherein said disease, disorder or condition is neuropathic pain or postherpetic pain.
 - 5. The method of claim 1, wherein said disease, disorder or condition is a neurodegenerative disease selected from the group consisting of: Alzheimer's disease; AIDS-related dementia; Parkinson's disease; amyotrophic lateral sclerosis; Huntington's disease; and Down's syndrome.
 - 6. The method of claim 1, wherein said disease, disorder or condition is an autoimmune disease selected from the group consisting of: systemic lupus erythmatosis; and multiple sclerosis.

30

25

- 7. The method of claim 1, wherein said disease, disorder or condition is of the gastrointestinal tract and is selected from the group consisting of: colitis; Crohn's disease; and irritable bowel syndrome.
- The method of claim 1, wherein said disease, disorder or condition is a vasospastic disease selected from the group consisting of: migraine headache; Reynaud's disease; and angina.
- 9. The method of claim 1, wherein said disease, disorder or condition is a skin disorder or condition selected from the group consisting of: sunburn; psoriasis; dermatitis; uticaria; and inflammation.
- The method of claim 1, wherein said disease, disorder or condition is a collagenrelated disorder selected from the group consisting of: fibrositis; scleroderma; and eosinophilic fascioliasis.
 - 11. The method of claim 1, wherein said disease, disorder or condition is hypertension or other cardiovascular disease or condition.
- The method of claim 1, wherein said disease, disorder or condition is a urinary tract disorder selected from the group consisting of: incontinence; cystitis; bladder hyperreflexia; and bladder hypermotility.
- The method of claim 1, wherein said disease, disorder or condition is an arthritic disease selected from the group consisting of: rheumatoid arthritis; and osteoarthritis.
 - 14. The method of claim 1, wherein said disease, disorder or condition is an ophthalmic disease or condition selected from the group consisting of: proliferative vitreoretinopathy; ocular injury; and conjunctivitis.
 - 15. The method of claim 1, wherein said disease, disorder or condition is small cell carcinoma of the lung or other cancer.

30

- 16. The method of claim 1, wherein said disease, disorder or condition is selected from the group consisting of oedema; emesis; a dysthymic disorder; and reflex sympathetic dystrophy.
- The method of any one of claims 1-16, wherein said peptidase is an exopeptidase selected from the group consisting of: dipeptidyl peptidase IV; quiescent cell proline dipeptidase; dipeptidyl peptidase 8; and attractin.
 - 18. The method of claim 17, wherein said exopeptidase is administered at a dose of between 1 μg and 1 mg.

10